The FDA made two peptide decisions, not one. BPC-157 is still in the slower lane.

The FDA made two different decisions about peptide shots on April 15. Most news outlets reported one of them and called it the whole story. They are not the same decision, and the difference matters for anyone following BPC-157, TB-500, and related peptides.

Decision one. Twelve peptides were removed from a restricted list, called Category 2, that the FDA uses to flag compounds with potential safety concerns. Compounding pharmacies are not allowed to make drugs from Category 2 ingredients. Removing a peptide from the list lifts that specific restriction.

Decision two. Seven peptides were scheduled for a separate FDA advisory committee review this July. That includes BPC-157 and TB-500, the two most-discussed compounds in the wellness community. Those seven cannot be legally made by compounding pharmacies until the committee votes and the FDA acts on the vote.

Twelve plus seven equals nineteen, which is the original size of the restricted list from 2023. Every peptide the FDA restricted back then is now either cleared or scheduled for review.

What some outlets got wrong. Being removed from the Category 2 list is not the same as being approved for legal use. There is a separate step, called 503A listing, that actually authorizes compounding pharmacies to make a drug. Most of the twelve peptides that came off Category 2 have not been added to the 503A list. They are in a middle zone: no longer formally restricted, but not yet formally permitted.

The political context. Health Secretary Robert F. Kennedy Jr. announced in February that the FDA would return roughly 14 peptides to legal compounding status "within a couple of weeks." Seven weeks later, the process reached a scheduling announcement, and the seven peptides most associated with his push (including BPC-157 and TB-500) are in the slower lane waiting for the July committee. That is a different timeline than the one he projected.

What the stock market did. Hims & Hers Health shares jumped 8-14% across the three days after the announcement. Most of the trading analysis linked the gain to the peptide decision. That is probably imprecise. Hims's compounded revenue is driven almost entirely by semaglutide and tirzepatide (Ozempic and Mounjaro compounded forms), which are a different legal category and are not directly affected by this decision. The move more likely reflects a general read that the FDA is moving toward compounding-friendly policy, not a specific judgement on these peptides.

What happens next. The July advisory committee meeting is the next concrete event. The committee has voted against compounding eligibility for similar peptides twice before, in October and December 2024. A meeting date is not a decision.

The one-sentence takeaway. Being off the restricted list is not the same as being on the permitted list, and the peptides most associated with the public conversation are still waiting for a vote.